ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03007810
Recruitment Status : Completed
First Posted : January 2, 2017
Last Update Posted : June 19, 2018
Sponsor:
Information provided by (Responsible Party):
Tianjin Hemay Bio-Tech Co., Ltd

Brief Summary:
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis. This study is the first administration of Hemay005 in humans to establish the initial safety, tolerability, and pharmacokinetic profile following single doses of Hemay005. A total of approximately 44 subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg), approximately 8 healthy subjects will be enrolled (6 active and 2 placebo) at each dose cohort by sentinel method(1 active and 1 placebo,5 active and 1 placebo), with the exception of 10mg (4 active) cohort. This study includes an 28-day Screening Period, a 1-day Treatment Period, and an End of Study Visit occurring approximately 11days (±3 days) after study drug administration.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Hemay005 Drug: Placebos Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: An Ascending Single Dose Study of the Pharmacokinetics, Safety and Tolerability of Hemay005 in Healthy Male Subjects
Study Start Date : December 2016
Actual Primary Completion Date : June 2018
Actual Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: Hemay005
Four subjects in cohort 1 and six subjects in each cohort (2 to 6) will receive Hemay005.
Drug: Hemay005
Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose

Placebo Comparator: Placebo
Two subjects in each cohort (cohorts 2 to 6) will receive placebo.
Drug: Placebos
Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose




Primary Outcome Measures :
  1. Number of adverse events and serious adverse events [ Time Frame: Day 1 up to Day 11±3 ]

Secondary Outcome Measures :
  1. Cmax [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose ]
    Maximum observed plasma concentration

  2. Tmax [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose ]
    Time of maximum concentration

  3. AUCt [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose ]
    Area under the plasma concentration-time curve from time zero extrapolated to infinity

  4. AUC∞ [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose ]
    Area under the plasma concentration-time curve from time zero to the last quantifiable concentration

  5. t1/2 [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose ]
    Terminal elimination half-life

  6. CL/F [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose ]
    Apparent total plasma clearance

  7. Vz/F [ Time Frame: pre-dose, 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48 hours post-dose ]
    Apparent total volume of distribution

  8. Cumulative urinary excretion [ Time Frame: pre-dose, 0-4 hours,4-8 hours,8-12 hours,12-24 hours,24-36 hours,36-48 hours post-dose ]
  9. Accumulative urine excretion rate [ Time Frame: pre-dose, 0-4 hours,4-8 hours,8-12 hours,12-24 hours,24-36 hours,36-48 hours post-dose ]
  10. Renal clearance [ Time Frame: pre-dose, 0-4 hours,4-8 hours,8-12 hours,12-24 hours,24-36 hours,36-48 hours post-dose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male subjects aged 18 to 60 years;
  2. Bodyweight(BW)≥ 50kg, Body mass index (BMI) in 18-28 (including upper and lower limit of the range);
  3. All male subjects must agree and commit to the use of a reliable contraceptive regimen(including vasoligation, abstinence, using a condom) for the duration of the study(from screening until 6 months after the last dose);
  4. Ability to understand and be willing to sign a written informed consent before study entry;
  5. Subjects would have good communication with the investigator and could comply with protocol.

Exclusion Criteria:

  1. A history of clinically severe gastrointestinal, hepatic, renal, cardiovascular, dermatological, immunological, respiratory, endocrine, oncological, neurological, metabolic, psychiatric disease or haematological disorders;
  2. Have a known history of hypersensitivity to any medicine or food, or allergy to the test article or any of the excipient of the test article;
  3. Have a gastrointestinal, hepatic or renal condition that may influence drug absorption or metabolism;
  4. A history of chronic infection (ie, tuberculosis);
  5. A medical history of any clinically significant medical disease or surgery within 4 weeks of the screening;
  6. Clinically significant laboratory abnormal results at screening or prior to the first dose of study drug;
  7. Clinically significant abnormal 12-lead ECG or vital signs ( systolic pressure <90 mmHg or >140 mmHg, diastolic pressure <50 mmHg or >90 mmHg; radial pulse rate <50 bpm or >100 bpm);
  8. Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen, or hepatitis C virus antibody at screening;
  9. Recent history of frequent alcohol consumption, defined by average intake of greater than 14 units of alcohol per week (1 unit = 360 mL beer or 45 mL of spirits with 40% alcohol content, or 150 mL wine), Participants who are unable to abstain from smoking during the study or quitting smoking for less than 3 months;
  10. Positive urine screen for drug and cigarettes, positive breath test for alcohol;
  11. Subjects who use soft drugs (ie marijuana )within 3 months of the screening and entire study duration or hard drugs (ie cocaine, phencyclidine ) within 1 year of the screening and entire study duration;
  12. Dietary habits or food intolerances which will interfere with the requirements for participants to consume a standardised diet whilst confined to the clinical unit;
  13. Participants who eat special food (Including grapefruit and/or Xanthine diet) for 14 days prior to dosing or any caffeine containing food or drinks, i.e. chocolate for 48 hours prior to dosing or drinking alcohol for 24 hours prior to dosing and not will stop to intake above food and drinks;
  14. Use of any drug that inhibits or induces hepatic metabolism of drugs within 30 days of planned study drug administration and entire study duration (e.g. inducers: barbiturates, carbamazepine, rifampicin, phenytoin, glucocorticoid and omeprazole; inhibitors - SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedatives and hypnotics, verapamil, fluoroquinolones and antihistamines);
  15. Participant who received any medicine within 14 days of the initial dose of study drug;
  16. Have received other clinical trials treatment within 3 months prior to study;
  17. Participants who have donated of blood (>400 mL) within 4 weeks of the study, or plan to donate of blood during of the study and 4 weeks after the study;
  18. Subjects cannot complete the study due to other reasons or by the investigator's judgment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03007810


Locations
China
Peking Union Medical College Hospital
Beijin, China
Sponsors and Collaborators
Tianjin Hemay Bio-Tech Co., Ltd

Responsible Party: Tianjin Hemay Bio-Tech Co., Ltd
ClinicalTrials.gov Identifier: NCT03007810     History of Changes
Other Study ID Numbers: HM005PS1S01
First Posted: January 2, 2017    Key Record Dates
Last Update Posted: June 19, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases